SES and SaT5G to Spearhead Development of Ubiquitous 5G Network Capabilities
29.6.2017 09:00:00 EEST | Business Wire | Press release
SES (Euronext Paris:SESG) (LuxX:SESG) announced today that the Satellite and Terrestrial Network for 5G (SaT5G) consortium, comprising SES and 15 further members, has been tasked to integrate satellite into 5G networks, enabling ubiquitous and instantaneous 5G coverage and capacity.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170628006574/en/
SES and SaT5G to Spearhead Development of Ubiquitous 5G Network Capabilities. (Photo: Business Wire)
Funded by the European Commission under the 5G PPP Phase 2 of the Horizon 2020 programme for Research & Innovation, the 30-month project will kick off in June 2017. It aims to deliver the seamless integration of satellite into 5G networks to ensure ubiquitous 5G access everywhere. The consortium will be focusing on extending 5G security to satellite, exploiting multicast for content distribution and driving relevant standardisation efforts mainly in 3rd Generation Partnership Project (3GPP) and European Telecommunications Standards Institute (ETSI). The key enabling technologies will be trialled and assessed through live testbed demonstrations across Europe.
Karim Michel Sabbagh, President and CEO at SES, said, “Maximum service coverage and capacity are key 5G deployment objectives, and these can be attained more effectively and quickly by the joint efforts of terrestrial and satellite infrastructures working together. SES’s geostationary orbit and medium earth orbit high throughput satellites are well positioned to provide massive capacity. Being the first of its kind, the SaT5G consortium is pleased to be spearheading the trials which will demonstrate these capabilities, and to cement Europe’s global leadership in 5G.”
About the SaT5G consortium
The Satellite and Terrestrial Network for 5G (SaT5G) consortium consists of 16 partners: Avanti Communications, Thales Alenia Space France, University of Surrey, SES, Airbus Defence and Space, OneAccess, TNO (Nederlandse Organisatie Voor Toegepast Natuurwetenschappelijk Onderzoek), British Telecommunications, Zodiac Inflight Innovations, Broadpeak, Gilat Satellite Networks, VT iDirect, imec, i2CAT Foundation, University of Oulu and Quortus. The consortium's main goal is to research, develop and validate key technologies required to enable the plug-and-play integration of satellite communications into 5G networks. The SaT5G consortium’s project coordinator is Avanti Communications.
Follow us on:
Twitter: https://twitter.com/SES_Satellites
LinkedIn: https://www.linkedin.com/company/ses
Facebook: https://www.facebook.com/SES.Satellites
YouTube: http://www.youtube.com/SESVideoChannel
Blog: https://www.ses.com/news/blogs
Media Gallery: https://www.ses.com/media-gallery
SES White papers are available under: https://www.ses.com/news/whitepapers
About SES
SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in two key business units: SES Video and SES Networks. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions. SES’s portfolio includes the ASTRA satellite system, which has the largest Direct-to-Home (DTH) television reach in Europe, O3b Networks, a global managed data communications service provider, and MX1, a leading media service provider that offers a full suite of innovative digital video and media services. Further information available at: www.ses.com
| This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 761413. |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170628006574/en/
Contact information
SES
Markus Payer, +352 710 725 500
Corporate Communications &
PR
Markus.Payer@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom